OVERVIEW
The global market for preclinical imaging is projected to hit USD 1,114.2 million by 2025; rising at a CAGR of 5.21% in 2020-2025. A number of factors such as technological advancements in molecular imaging, increased consumer demand for non-invasive small animal imaging techniques, and a increasing number of public-private partnerships and funding to support preclinical research are driving the growth of the global market for preclinical imaging.
TABLE OF CONTENT
1 Global Preclinical Imaging (In-VIVO) Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope
2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
3 Global Preclinical Imaging (In-VIVO) Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography
4 Global Preclinical Imaging (In-VIVO) Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis
5 Global Preclinical Imaging (In-VIVO) Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies
6 Global Preclinical Imaging (In-VIVO) Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7 Global Preclinical Imaging (In-VIVO) Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Supplier and distributor analysis (Market share and product dealing strategies)
8 Global Preclinical Imaging (In-VIVO) Market – By Modality (Market Size – & million/billion)
8.1 Optical Imaging Systems
8.2 Preclinical Nuclear Imaging Systems
8.3 Micro-Ultrasound Systems
8.4 Micro-CT Systems
8.5 Preclinical Magnetic Particle Imaging (MPI) Systems
8.6 Others
9 Global Preclinical Imaging (In-VIVO) Market – By Reagents
9.1 Preclinical Optical Imaging Reagents
9.2 Preclinical MRI Contrast Agents
9.3 Preclinical Nuclear Imaging Reagents
9.4 Preclinical Ultrasound Contrast Agents
9.5 Preclinical CT Contrast Agents
10 Global Preclinical Imaging (In-VIVO) Market – By Geography (Market Size – &
million/billion)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 U.K
10.3.2 Germany
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia-Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 South Korea
10.4.5 Rest of APAC
10.5 Rest of the World
10.5.1 South America
10.5.2 Middle East
10.5.3 Africa
11 Global Preclinical Imaging (In-VIVO) Market – Entropy
11.1 New product launches
11.2 M&A’s, collaborations, JVs and partnerships
12 Global Preclinical Imaging (In-VIVO) Market Company Profile (Key Players)
12.1 Market Share, Company Revenue, Products, M&A, Developments
12.2 Fujifilm Holdings Corporation
12.3 Bruker Corporation
12.4 Perkinelmer, Inc.
12.5 Milabs B.V.
12.6 Trifoil Imaging
12.7 Miltenyi Biotec GmbH
12.8 Mediso Ltd.
12.9 Aspect Imaging Ltd.
12.10 MR Solutions Ltd.
12.11 Li-Cor Biosciences
12.12 Company 11 & more
13 Global Preclinical Imaging (In-VIVO) Market – Appendix
13.1 Sources
13.2 Abbreviations